Owning 44% shares,institutional owners seem interested in Lexeo Therapeutics, Inc. (NASDAQ:LXEO), [Yahoo! Finance]
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: Yahoo! Finance
52% of the business is held by the top 8 shareholders Insiders have been selling lately Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. If you want to know who really controls Lexeo Therapeutics, Inc. ( NASDAQ:LXEO ), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 44% to be precise, is institutions. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. Let's take a closer look to see what the different types of shareholders can tell us about Lexeo Therapeutics. View our late
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) ForumGlobeNewswire
- Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LXEO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Lexeo Therapeutics: Behind The Rebound [Seeking Alpha]Seeking Alpha
LXEO
Earnings
- 8/14/25 - Beat
LXEO
Sec Filings
- 11/28/25 - Form EFFECT
- 11/26/25 - Form 424B3
- 11/20/25 - Form 4
- LXEO's page on the SEC website